Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Eur J Hosp Pharm. 2022 Jul;29(4):235-236. doi: 10.1136/ejhpharm-2020-002660. Epub 2021 Apr 21.
A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week benralizumab dosing interval, discussion arose as to whether benralizumab should be administered or if treatment should be discontinued, due to the lack of experience with benralizumab in this situation. Severe broncho-obstruction developed, and the next injection of benralizumab was administered during ICU admission without detrimental symptoms. With this case report, we would like to share our experience with the safe administration of benralizumab during COVID-19 pneumonia, guiding doctors in future decision making.
一名接受贝那鲁肽治疗的重症哮喘患者因 2019 年冠状病毒病（COVID-19）感染而入住重症监护病房（ICU）。在贝那鲁肽 8 周给药间隔结束时，由于在这种情况下缺乏贝那鲁肽的经验，出现了是否应给予贝那鲁肽或停止治疗的讨论。严重的支气管阻塞发展，在 ICU 住院期间给予了下一次贝那鲁肽注射，没有出现有害症状。通过本病例报告，我们希望分享我们在 COVID-19 肺炎期间安全使用贝那鲁肽的经验，为未来的决策提供指导。
